skip to main content
Idioma:

Linked Pharmacometric‐Pharmacoeconomic Modeling and Simulation in Clinical Drug Development

Hill‐McManus, Daniel ; Marshall, Scott ; Liu, Jing ; Willke, Richard J. ; Hughes, Dyfrig A.

Clinical pharmacology and therapeutics, 2021-07, Vol.110 (1), p.49-63 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
  • Título:
    Linked Pharmacometric‐Pharmacoeconomic Modeling and Simulation in Clinical Drug Development
  • Autor: Hill‐McManus, Daniel ; Marshall, Scott ; Liu, Jing ; Willke, Richard J. ; Hughes, Dyfrig A.
  • É parte de: Clinical pharmacology and therapeutics, 2021-07, Vol.110 (1), p.49-63
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
  • Descrição: Market access and pricing of pharmaceuticals are increasingly contingent on the ability to demonstrate comparative effectiveness and cost‐effectiveness. As such, it is widely recognized that predictions of the economic potential of drug candidates in development could inform decisions across the product life cycle. This may be challenging when safety and efficacy profiles in terms of the relevant clinical outcomes are unknown or highly uncertain early in product development. Linking pharmacometrics and pharmacoeconomics, such that outputs from pharmacometric models serve as inputs to pharmacoeconomic models, may provide a framework for extrapolating from early‐phase studies to predict economic outcomes and characterize decision uncertainty. This article reviews the published studies that have implemented this methodology and used simulation to inform drug development decisions and/or to optimize the use of drug treatments. Some of the key practical issues involved in linking pharmacometrics and pharmacoeconomics, including the choice of final outcome measures, methods of incorporating evidence on comparator treatments, approaches to handling multiple intermediate end points, approaches to quantifying uncertainty, and issues of model validation are also discussed. Finally, we have considered the potential barriers that may have limited the adoption of this methodology and suggest that closer alignment between the disciplines of clinical pharmacology, pharmacometrics, and pharmacoeconomics, may help to realize the potential benefits associated with linked pharmacometric‐pharmacoeconomic modeling and simulation.
  • Editor: United States
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  2 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.